Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma SubgroupsStefan G. van Ravensteijn, Ingrid M.E. Desar, Yvonne M.H. Versleijen‐Jonkers et al.|Cancers|2022Cited by 19
Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Kalijn F. Bol et al.|Clinical Cancer Research|2025Cited by 6
Supplementary Table 2 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Jacco J. de Haan et al.|Unknown|2025Cited by 0
Supplementary Table 4 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Jacco J. de Haan et al.|Unknown|2025Cited by 0
Supplementary Figure 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Jacco J. de Haan et al.|Unknown|2025Cited by 0